Dear Friends from near and far:
The National Institutes of Health in the United States of America still needs some more patients who have a diagnosis of Hereditary Inclusion Body Myopathy to complete their phase 1 trial with ManNac, and the natural history study. I have participated in one of their studies and I can attest to the excellent care and state of the art equipment. Their researchers and doctors are beyond comparasion.
Because HIBM is rare, we need all the patients with HIBM who are willing to contact NIH and participate in the trials.
Here is the description and a link at the bottom of the page. Please feel free to ask me any questions.
ClinicalTrials.gov Identifier:
NCT01634750
First received: July 3, 2012
Last updated: December 8, 2012
Last verified: September 2012
History of Changes
Full Text View Tabular ViewNo Study Results PostedDisclaimerHow to Read a Study Record
Purpose
Background:
- Hereditary inclusion body myopathy (HIBM) is a genetic disorder caused by mutations in a gene called GNE. This gene is responsible for producing a sugar called sialic acid. Low levels of sialic acid may cause muscle problems. Symptoms of HIBM include walking difficulties and muscle weakness, which usually start in a person's 20s or 30s and become worse over time.
Researchers are studying a drug called ManNAc. It may be useful for treating HIBM. However, this drug is still being tested. Researchers want to see how ManNAc is absorbed into and removed from the blood. They will not be looking specifically at whether ManNAc can stop or slow the symptoms of HIBM.
Objectives:
To study how MaNAc is absorbed into and removed from the blood in people with HIBM.
To study of safety of ManNAc in people with HIBM.
Eligibility:
- Individuals between 18 and 70 years of age who have HIBM.
Design:
Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
Participants will have a 3 to 4-day inpatient stay for the main part of the study.
Participants will be divided into groups of six. In each group, four will take ManNAc and two will take a placebo. Participants will not know which one they will receive.
Participants will have a single dose of either ManNAc or placebo. They will be monitored for any possible side effects. Frequent blood samples will be collected during the 4-day stay.
No treatment for HIBM will be provided as part of this study.
Condition Intervention Phase
Hereditary Inclusion Body Myopathy (HIBM)
GNE Myopathy
Drug: ManNAc
Phase 1
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Resource links provided by NLM:
Genetics Home Reference related topics: inclusion body myopathy 2
MedlinePlus related topics: Muscle Disorders
U.S. FDA Resources
Further study details as provided by National Institutes of Health Clinical Center (CC):
Primary Outcome Measures:
To evaluate the safety and tolerability of a single dose of orally administered ManNAc to HIBM subjects. [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
Pharmacokinetics
Estimated Enrollment: 22
Study Start Date: September 2012
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ManNac Drug: ManNAc
Single dose
Placebo Comparator: Placebo Drug: ManNAc
Single dose
Detailed Description:
Hereditary inclusion body myopathy (HIBM) is an autosomal recessive, neuromuscular disorder characterized by progressive muscle weakness with onset in early adulthood. The causative gene, GNE, codes for the bifunctional enzyme uridine diphospho-N-acetylglucosamine (UDP-GlcNAc)-2-epimerase/N-acetylmannosamine (ManNAc) kinase (GNE/MNK), which catalyzes the first 2 steps in the biosynthesis of sialic acid. The subsequent paucity of sialic acid production is presumed to cause decreased sialylation of HIBM muscle glycoproteins, resulting in muscle deterioration. In this Phase 1, randomized, placebo-controlled, double-blind, escalating single-dose study, we propose to provide ManNAc (N-acetyl-D-mannosamine monohydrate) orally as a liquid solution to 3 cohorts of 6 subjects (Cohorts A, B, C) at doses of 3,000 mg, 6,000 mg, and 10,000 mg ManNAc, respectively, or up to the maximum tolerated dose (MTD). The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single dose of orally administered ManNAc to HIBM subjects, to identify the MTD of a single dose of orally administered ManNAc to HIBM subjects, and to explore the effect of a single dose of ManNAc on potential pharmacodynamic (PD) markers of HIBM. All subjects will be randomly assigned in a 2:1 ratio to receive ManNAc (n equals 4) or placebo (n equals 2) and the decision to dose-escalate will be the responsibility of the Safety Review Committee (SRC). Safety will be assessed by adverse events (AEs), clinical laboratory tests, vital signs, physical examinations, and electrocardiograms (ECGs). PK will be assessed for both ManNAc and sialic acid. PD will be assessed by some of the following exploratory biomarkers: serum transferrin sialylation status; plasma glycan profiles; and plasma, white cell, platelet, and urine sialylation status (free and bound sialic acid N-acetylneuraminic acid (Neu5Ac) and cytidine 5-monophosphate CMP-Neu5Ac).
Eligibility
Ages Eligible for Study: 18 Years to 70 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria
INCLUSIONI CRITERIA:
Subject is 18-70 years, either gender, inclusive.
Subject has a diagnosis of HIBM (or IBM2, GNE myopathy, DMRV or Nonaka myopathy) based upon a consistent clinical course and identification of 2 GNE mutations. Molecular confirmation of the diagnosis will be obtained for all subjects in the study.
Subject must be willing to stop any treatment with ManNAc, sialic acid, IVIG, and/or other supplements containing sialic acid (eg, St John's wort, sialyllactose) 30 days prior to randomization and remain off such treatment for the duration of the trial.
Subject has the ability to travel to the NIH Clinical Center (CC) for admissions.
Subject (if a woman of reproductive age) must be willing to use an effective method of contraception for the duration of the trial.
Subject provides written informed consent.
EXCLUSION CRITERIA:
.-.Subject has a severe disease manifestation that would interfere with the ability to comply with the requirements of this protocol.
Subject has a psychiatric illness or neurological disease that would interfere with the ability to comply with the requirements of this protocol. This includes, but is not limited to, uncontrolled/untreated psychotic depression, bipolar disorder, schizophrenia, substance abuse or dependence, antisocial personality disorder, or panic disorder.
Subject has hepatic laboratory parameters (AST, ALT, GGTP), or renal laboratory parameters (creatinine, BUN) greater than 3 times the upper limit of normal.
Subject has a QTcB > 450 msec (males) or QTcB > 470 msec (females).
Subject is anemic (defined as two standard deviations below normal for age and gender).
Subject shows evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, or gastrointestinal disease, or has a condition that requires immediate surgical intervention.
Subject is pregnant or breastfeeding at any time during the study.
Subject has received treatment with another investigational drug, investigational device, or approved therapy for investigational use within 4 weeks of initial screening.
Subject has a hypersensitivity to ManNAc or in the judgment of the investigator, has a condition that places the subject at increased risk for adverse effects.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01634750
Contacts
Contact: Lea Latham, CRNP (301) 827-9235 llatham@mail.nih.gov
Contact: Nuria Carrillo-Carrasco, M.D. (301) 402-2324 carrilln@mail.nih.gov
Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: David Draper 301-827-9636 draperd@mail.nih.gov
Sponsors and Collaborators
National Human Genome Research Institute (NHGRI)
National Center for Advancing Translational Science (NCATS)
Therapeutics for Rare and Neglected Diseases (TRND)
Investigators
Principal Investigator: Nuria Carrillo-Carrasco, M.D. National Human Genome Research Institute (NHGRI)
More Information
Additional Information:
NIH Clinical Center Detailed Web Page
Publications:
Amir SM, Barker SA, Butt WR, Crooke AC, Davies AG. Administration of N-acetyl-D-mannosamine to mammals. Nature. 1966 Aug 27;211(5052):976-7.
Argov Z, Mitrani-Rosenbaum S. The hereditary inclusion body myopathy enigma and its future therapy. Neurotherapeutics. 2008 Oct;5(4):633-7. Review.
Bork K, Reutter W, Gerardy-Schahn R, Horstkorte R. The intracellular concentration of sialic acid regulates the polysialylation of the neural cell adhesion molecule. FEBS Lett. 2005 Sep 12;579(22):5079-83.
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )
ClinicalTrials.gov Identifier: NCT01634750 History of Changes
Other Study ID Numbers: 120207, 12-HG-0207
Study First Received: July 3, 2012
Last Updated: December 8, 2012
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on January 21, 2013
TO TOP
For Patients & Families For Researchers For Study Record Managers
HOME RSS FEEDS SITE MAP TERMS AND CONDITIONS DISCLAIMER CONTACT NLM HELP DESK
Copyright Privacy Accessibility Viewers & Players Freedom of Information Act USA.gov
http://www.clinicaltrials.gov/ct2/show/NCT01634750?term=hibm&rank=1
